PLSE
Pulse Biosciences, Inc. NASDAQ Listed May 18, 2016$19.59
Mkt Cap $1.3B
52w Low $12.56
51.2% of range
52w High $26.30
50d MA $20.81
200d MA $17.25
P/E (TTM)
-19.3x
EV/EBITDA
-11.9x
P/B
17.4x
Debt/Equity
0.1x
ROE
-90.2%
P/FCF
-17.0x
RSI (14)
—
ATR (14)
—
Beta
1.69
50d MA
$20.81
200d MA
$17.25
Avg Volume
365.4K
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
3957 Point Eden Way · Miami, CA 94545 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | AMC | -0.32 | -0.27 | +15.6% | 20.03 | +0.0% | -6.9% | +3.0% | +2.0% | -2.6% | — | — |
| Feb 19, 2026 | AMC | -0.27 | -0.26 | +1.9% | 25.08 | -2.6% | -14.6% | -5.7% | -5.9% | +1.2% | +0.4% | — |
| Nov 5, 2025 | AMC | -0.31 | -0.29 | +6.5% | 16.27 | -8.1% | -3.3% | -1.7% | -0.6% | -0.3% | -2.1% | — |
| Aug 12, 2025 | AMC | -0.26 | -0.28 | -7.7% | 15.10 | +1.3% | +11.2% | +3.1% | -6.6% | -3.0% | +1.1% | — |
| May 8, 2025 | AMC | — | -0.17 | — | 16.85 | -0.4% | +1.3% | -1.6% | +0.3% | -3.2% | +1.2% | — |
| Mar 27, 2025 | AMC | -0.24 | -0.17 | +29.2% | 15.66 | +4.5% | +6.0% | -3.1% | -0.9% | +5.0% | -13.2% | — |
| Oct 30, 2024 | AMC | -0.24 | -0.16 | +33.3% | 17.72 | +1.0% | -1.6% | -16.5% | +4.3% | +8.4% | +9.6% | — |
| Aug 19, 2024 | TNS | -0.24 | -0.20 | +17.0% | 19.96 | -0.1% | -3.9% | +13.8% | -1.4% | -0.2% | -4.4% | — |
| Aug 12, 2024 | AMC | -0.24 | -0.20 | +16.7% | 15.65 | +2.9% | +8.1% | -0.5% | +13.5% | -0.4% | +5.0% | — |
| May 7, 2024 | AMC | -0.24 | -0.14 | +41.7% | 7.60 | -2.9% | -9.2% | +0.7% | +7.2% | -4.0% | +7.6% | — |
| Mar 28, 2024 | AMC | -0.24 | -0.15 | +37.5% | 8.71 | -11.6% | -8.3% | -3.8% | +3.3% | -4.2% | -0.5% | — |
| Nov 13, 2023 | AMC | -0.24 | -0.15 | +37.5% | 5.41 | +1.7% | +7.6% | +9.6% | -2.2% | -1.9% | +2.3% | — |
| Aug 10, 2023 | AMC | -0.22 | -0.19 | +13.6% | 6.84 | +12.6% | +5.6% | +7.1% | +2.5% | -0.3% | +0.5% | — |
| May 11, 2023 | TNS | -0.22 | -0.23 | -4.5% | 7.61 | +0.0% | +6.3% | -1.0% | -1.1% | -3.0% | -5.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 21 | Maxim Group | Downgrade | Buy → Hold | — | $1.39 | $1.40 | +0.7% | +7.2% | +12.1% | -8.4% | +18.3% | -10.5% |
| May 13 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.48 | $1.56 | +5.4% | +14.9% | +26.5% | +3.3% | -4.1% | +0.5% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.86 | $4.18 | -14.0% | -27.0% | +0.0% | +4.8% | +5.4% | -8.4% |
| Apr 1 | Stephens & Co. | Maintains | Overweight → Overweight | — | $4.86 | $4.18 | -14.0% | -27.0% | +0.0% | +4.8% | +5.4% | -8.4% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.44 | $6.42 | -0.3% | +5.0% | -2.1% | -3.2% | +2.5% | +0.8% |
| Nov 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.68 | $22.16 | +2.2% | -0.5% | -0.1% | -5.0% | +4.1% | -1.0% |
| Jul 27 | Stephens & Co. | Maintains | Overweight → Overweight | — | $19.50 | $20.10 | +3.1% | +5.1% | +3.2% | +0.3% | -3.4% | +1.3% |
| Mar 11 | Maxim Group | Maintains | Buy → Buy | — | $28.80 | $29.51 | +2.5% | +5.0% | +2.1% | +0.9% | -15.6% | -2.3% |
| Jan 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.84 | $35.50 | +1.9% | -1.7% | +0.6% | -0.0% | -0.8% | -0.6% |
| May 12 | H.C. Wainwright | Upgrade | Neutral → Buy | — | $11.74 | $12.22 | +4.1% | +11.5% | -12.6% | +0.2% | -5.5% | -1.6% |
| May 12 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $11.74 | $12.22 | +4.1% | +11.5% | -12.6% | +0.2% | -5.5% | -1.6% |
| Feb 14 | H.C. Wainwright | Downgrade | Buy → Neutral | — | $12.18 | $7.00 | -42.5% | -29.8% | -5.0% | -5.2% | -1.2% | -7.8% |
| Feb 14 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $12.18 | $7.00 | -42.5% | -29.8% | -5.0% | -5.2% | -1.2% | -7.8% |
| Feb 25 | H.C. Wainwright | Maintains | Buy → Buy | — | $18.23 | $18.45 | +1.2% | -0.9% | +2.4% | -3.9% | +0.4% | +8.1% |
No insider trades available.
8-K · 2.02
!! High
Pulse Biosciences, Inc. -- 8-K 2.02: Earnings Results
Pulse Biosciences reported Q1 2026 financial results, providing investors with updated operational performance metrics and financial condition details for the quarter ending March 31, 2026.
May 4
8-K · 7.01
! Medium
Pulse Biosciences, Inc -- 8-K 7.01: Regulation FD Disclosure
Pulse Biosciences presented clinical data on its cardiac arrhythmia technology at Heart Rhythm 2026, potentially validating its therapeutic approach and supporting future commercialization efforts.
Apr 27
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
This vague Regulation FD disclosure provides no material information about PLSE, leaving investors without clarity on what management actually communicated or why it matters for valuation.
Apr 16
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Abbott's failure to promote Teplitsky to COO signals internal management instability and potential leadership challenges, which could concern investors about strategic direction and executive bench strength.
Apr 9
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Pulse Biosciences announced a material event via press release, but the filing provides insufficient detail to assess impact; investors should review the complete press release in the 8-K exhibit for specifics on clinical, commercial, or financial developments.
Apr 7
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
I need more specific information about the executive change to provide a meaningful analysis. The filing summary lacks details about who left/joined, their role, and circumstances, making it impossible to assess the stock impact accurately.
Mar 27
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Pulse Biosciences' announced strategic realignment and exceptional long-term atrial fibrillation clinical data validates its cardiac catheter program, potentially accelerating commercialization and revenue growth for the medical device company.
Mar 17
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Pulse Systems gained FDA clearance for its Vybrance System, a head and neck surgery advancement, which could drive revenue growth and strengthen its competitive position in the surgical device market.
Mar 12
8-K · 8.01
!! High
Pulse Biosciences, Inc -- 8-K 8.01: Material Event / Announcement
Pulse Biosciences presented clinical data on its interventional thyroidology technology at a 2026 medical conference, potentially validating the company's treatment approach and supporting future commercialization efforts.
Mar 9
8-K · 7.01
! Medium
Pulse Biosciences, Inc -- 8-K 7.01: Regulation FD Disclosure
Pulse Biosciences disclosed an updated investor presentation highlighting next-generation nPulse cardiac catheter development and strengthened focus on EP cardiac ablation following promising clinical outcomes data.
Mar 3
8-K · 5.02
!!! Very High
Pulse Biosciences, Inc -- 8-K 5.02: Executive Change
Pulse Biosciences' Chief Commercial Officer departure may signal leadership transitions as the company navigates its commercial strategy and market operations going forward.
Mar 2
8-K · 5.02
!!! Very High
Pulse Biosciences, Inc -- 8-K 5.02: Executive Change
Pulse Biosciences' Chief Commercial Officer resigned without disagreement with the company, signaling an amicable departure that shouldn't raise concerns about operational or financial issues.
Feb 27
8-K
Pulse Biosciences, Inc -- 8-K Filing
Pulse Biosciences released fourth quarter and full-year 2025 financial results alongside business updates, providing investors with recent operational performance and strategic progress information.
Feb 19
8-K · 1.01
!! High
Pulse Biosciences, Inc -- 8-K 1.01: Material Agreement
Pulse Biosciences established an at-the-market offering agreement with TD Cowen, allowing flexible share sales without obligation, giving the company discretionary capital-raising optionality.
Feb 19
8-K · 8.01
!! High
Pulse Biosciences, Inc -- 8-K 8.01: Material Event / Announcement
Pulse Biosciences presented clinical data on its nPulse Cardiac Catheter System for atrial fibrillation treatment at a major cardiology conference, demonstrating initial safety and effectiveness in the ongoing study.
Feb 6
Data updated apr 26, 2026 7:58pm
· Source: massive.com